Progress in biomedicine is not all about new methodologies, new empirical findings and new patents. It is also about new metaphors that guide and connect research efforts, technological innovation, investment activities, public opinion, and health political initiatives.
Some metaphors are pushed over and over again, but never seem to take off — like the notion of “biosemiotics” which continuous to be a largely unsuccesful philosophical favourite within a small circle of devout believers (for some reason there are quite a few of them here in Denmark).
Other metaphors are extremely succesful, at least for the time being – like the notion of “high throughput analysis” which seems to be all over the place: in scientific papers, in applications for funding, in advertisements, and so forth. Together with the word “robust”, the phrase ”high throughput analysis” is like an open sesame which, in careful dosage, gives you a competetive advantage in the race for funding and fame. Probably because it is a connecting metaphor between the spheres of bioscience and economy. ”High throughput” is a word that both venture capitalists, biotech CEOs and lab bench workers can understand.
Continue Reading »